Additive effects of fecal microbiota transplantation and infliximab on gut microbiome and metabolome in refractory inflammatory bowel disease patients

Puntos clave

• The research aims to investigate how fecal microbiota transplantation and infliximab together affect the gut microbiome and metabolome in patients with refractory inflammatory bowel disease.
• Registered as ClinicalTrials.gov NCT07149441
• Evaluated effects on gut microbiome and metabolome
• Included patients with refractory inflammatory bowel disease
• Combined treatment improved gut microbiome diversity
• Metabolomic analysis showed enhanced metabolic profiles
• Indications of better disease management in treated individuals